Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Leuk Res. 2019 Feb:77:30-33. doi: 10.1016/j.leukres.2018.12.011. Epub 2018 Dec 24.

¹ Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Indianapolis, IN, USA. Electronic address: [email protected].
² Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Indianapolis, IN, USA.
³ Department of medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁴ Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Indianapolis, IN, USA; Veterans Affairs Medical Center, Indianapolis, IN, USA.

No abstract available

Keywords: AML; Acute myeloid leukemia; Bortezomib; Sorafenib; Vorinostat.

Publication types